$9.67
1.45%
Downside
Day's Volatility :8.54%
Upside
7.2%
76.73%
Downside
52 Weeks Volatility :80.84%
Upside
17.67%
Period | Delcath Systems Inc | Index (Russel 2000) |
---|---|---|
3 Months | 47.63% | 0.0% |
6 Months | 142.36% | 0.0% |
1 Year | 110.22% | 0.0% |
3 Years | -6.84% | -22.3% |
Market Capitalization | 270.8M |
Book Value | $0.15 |
Earnings Per Share (EPS) | -2.52 |
Wall Street Target Price | 21.33 |
Profit Margin | 0.0% |
Operating Margin TTM | -50.37% |
Return On Assets TTM | -81.99% |
Return On Equity TTM | -478.59% |
Revenue TTM | 11.9M |
Revenue Per Share TTM | 0.51 |
Quarterly Revenue Growth YOY | 1468.9% |
Gross Profit TTM | 2.0M |
EBITDA | -35.9M |
Diluted Eps TTM | -2.52 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.34 |
EPS Estimate Next Year | -0.25 |
EPS Estimate Current Quarter | -0.36 |
EPS Estimate Next Quarter | -0.31 |
What analysts predicted
Upside of 120.58%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 3.4M | ↑ 25.49% |
Net Income | -19.2M | ↓ 57.4% |
Net Profit Margin | -564.19% | ↑ 1097.58% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 1.6M | ↓ 53.62% |
Net Income | -13.6M | ↓ 29.11% |
Net Profit Margin | -862.47% | ↓ 298.28% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 1.6M | ↑ 4.18% |
Net Income | -24.5M | ↑ 79.68% |
Net Profit Margin | -1.5K% | ↓ 625.08% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 3.6M | ↑ 115.98% |
Net Income | -26.8M | ↑ 9.28% |
Net Profit Margin | -752.66% | ↑ 734.89% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 2.7M | ↓ 23.52% |
Net Income | -39.2M | ↑ 46.37% |
Net Profit Margin | -1.4K% | ↓ 687.69% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 2.1M | ↓ 24.05% |
Net Income | -47.7M | ↑ 21.74% |
Net Profit Margin | -2.3K% | ↓ 868.51% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 597.0K | ↓ 6.57% |
Net Income | -10.4M | ↓ 14.31% |
Net Profit Margin | -1.7K% | ↑ 156.79% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 495.0K | ↓ 17.09% |
Net Income | -7.2M | ↓ 30.5% |
Net Profit Margin | -1.5K% | ↑ 280.9% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 434.0K | ↓ 12.32% |
Net Income | -20.3M | ↑ 182.42% |
Net Profit Margin | -4.7K% | ↓ 3231.69% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 539.0K | ↑ 24.19% |
Net Income | -11.1M | ↓ 45.25% |
Net Profit Margin | -2.1K% | ↑ 2620.59% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 3.1M | ↑ 482.37% |
Net Income | -11.1M | ↓ 0.22% |
Net Profit Margin | -353.97% | ↑ 1712.08% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 7.8M | ↑ 147.4% |
Net Income | -13.7M | ↑ 23.67% |
Net Profit Margin | -176.94% | ↑ 177.03% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 6.8M | ↓ 22.99% |
Total Liabilities | 21.8M | ↑ 165.36% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 14.2M | ↑ 107.66% |
Total Liabilities | 20.6M | ↓ 5.57% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 34.6M | ↑ 143.7% |
Total Liabilities | 12.6M | ↓ 38.95% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 33.1M | ↓ 4.36% |
Total Liabilities | 21.2M | ↑ 68.61% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 17.9M | ↓ 46.08% |
Total Liabilities | 23.7M | ↑ 12.04% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 38.6M | ↑ 116.17% |
Total Liabilities | 22.8M | ↓ 3.73% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 30.6M | ↑ 71.31% |
Total Liabilities | 43.7M | ↑ 84.12% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 21.1M | ↓ 31.21% |
Total Liabilities | 21.3M | ↓ 51.25% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 47.6M | ↑ 126.02% |
Total Liabilities | 22.9M | ↑ 7.35% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 38.6M | ↓ 18.84% |
Total Liabilities | 22.8M | ↓ 0.1% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 36.1M | ↓ 6.51% |
Total Liabilities | 21.5M | ↓ 5.94% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 33.9M | ↓ 6.06% |
Total Liabilities | 29.7M | ↑ 38.37% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -14.7M | ↓ 4.33% |
Investing Cash Flow | -76.0K | ↓ 85.5% |
Financing Cash Flow | 13.2M | ↓ 14.3% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -23.7M | ↑ 60.81% |
Investing Cash Flow | -24.0K | ↓ 68.42% |
Financing Cash Flow | 30.3M | ↑ 128.96% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -22.9M | ↓ 3.47% |
Investing Cash Flow | -782.0K | ↑ 3158.33% |
Financing Cash Flow | 42.4M | ↑ 39.76% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -22.6M | ↓ 1.15% |
Investing Cash Flow | -143.0K | ↓ 81.71% |
Financing Cash Flow | 20.8M | ↓ 50.84% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -25.0M | ↑ 10.38% |
Investing Cash Flow | -209.0K | ↑ 46.15% |
Financing Cash Flow | 10.1M | ↓ 51.29% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.3M | ↓ 42.06% |
Investing Cash Flow | -40.0K | ↑ 0.0% |
Financing Cash Flow | 16.7M | ↑ 218.16% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -9.6M | ↑ 126.27% |
Investing Cash Flow | -40.0K | ↑ 0.0% |
Financing Cash Flow | 7.0K | ↓ 99.96% |
Sell
Neutral
Buy
Delcath Systems Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Delcath Systems Inc | 24.13% | 142.36% | 110.22% | -6.84% | 26.24% |
![]() Stryker Corporation | 12.3% | 0.36% | 24.19% | 28.8% | 65.26% |
![]() Boston Scientific Corp. | 10.6% | 20.32% | 51.42% | 80.93% | 95.5% |
![]() Edwards Lifesciences Corp. | 9.4% | -28.78% | -12.2% | -45.23% | -7.73% |
![]() Abbott Laboratories | 3.57% | -5.84% | 13.1% | -11.32% | 35.19% |
![]() Medtronic Plc | 10.85% | 5.57% | 12.46% | -33.2% | -16.71% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Delcath Systems Inc | NA | NA | NA | -1.34 | -4.79 | -0.82 | NA | 0.15 |
![]() Stryker Corporation | 39.84 | 39.84 | 2.64 | 12.0 | 0.19 | 0.07 | 0.01 | 51.86 |
![]() Boston Scientific Corp. | 66.34 | 66.34 | 2.01 | 2.41 | 0.09 | 0.05 | NA | 13.85 |
![]() Edwards Lifesciences Corp. | 26.3 | 26.3 | 3.2 | 2.69 | 0.22 | 0.12 | NA | 12.35 |
![]() Abbott Laboratories | 35.92 | 35.92 | 4.16 | 4.66 | 0.14 | 0.06 | 0.02 | 22.6 |
![]() Medtronic Plc | 30.16 | 30.16 | 1.66 | 5.2 | 0.08 | 0.04 | 0.03 | 37.39 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Delcath Systems Inc | Buy | $270.8M | 26.24% | NA | 0.0% |
![]() Stryker Corporation | Buy | $136.8B | 65.26% | 39.84 | 16.12% |
![]() Boston Scientific Corp. | Buy | $120.2B | 95.5% | 66.34 | 12.0% |
![]() Edwards Lifesciences Corp. | Buy | $40.2B | -7.73% | 26.3 | 23.74% |
![]() Abbott Laboratories | Buy | $198.1B | 35.19% | 35.92 | 13.65% |
![]() Medtronic Plc | Buy | $115.3B | -16.71% | 30.16 | 12.06% |
Insights on Delcath Systems Inc
Revenue is up for the last 4 quarters, 434.0K → 7.76M (in $), with an average increase of 54.0% per quarter
Netprofit is down for the last 2 quarters, -11.11M → -13.74M (in $), with an average decrease of 23.7% per quarter
In the last 3 years, Boston Scientific Corp. has given 80.9% return, outperforming this stock by 87.7%
Rosalind Advisors, Inc.
AIGH Capital Management, LLC
Vivo Capital, LLC
Bvf Inc
Vanguard Group Inc
Essex Investment Management Company, LLC
delcath systems, inc. (nasdaq- dcth) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. our proprietary product---melphalan hydrochloride for injection for use with the delcath hepatic delivery system (melphalan/hds)---is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure. delcath is in late-stage clinical development in the united states with initial commercial activities in europe, where the melphalan/hds is marketed as a ce marked device under the trade name delcath hepatic chemosat® delivery system for melphalan (chemosat). our commercial strategy for chemosat is to steadily grow clinical adoption in major european markets and utilize physician experience to support appeals for reimbursement. since launch over 250 chemosat treatments have been performed at over 20 leading european cancer centers. in 2016, we launched our focus pivotal study in hepatic dominant ocular
Organization | Delcath Systems Inc |
Employees | 76 |
CEO | Mr. Gerard J. Michel MBA, MS |
Industry | Medical Specialties |
A Spac I Acquisition Corp
$9.67
-7.46%
Keyarch Acquisition Corp
$9.67
-7.46%
Connexa Sports Technologies Inc
$9.67
-7.46%
Us Value Etf
$9.67
-7.46%
First Wave Biopharma Inc
$9.67
-7.46%
Global X Msci Next Emerging
$9.67
-7.46%
Fat Projects Acquisition Corp
$9.67
-7.46%
Capital Link Global Fintech
$9.67
-7.46%
Applied Uv Inc
$9.67
-7.46%